5 Days
Source:
The Boston Globe
_1777370220974_847775619.png&w=48&q=75){kind=small}
FDA panel approves Moderna flu shot
A panel of FDA advisers unanimously endorsed Moderna's seasonal mRNA flu vaccine, affirming that its benefits outweigh risks for adults aged 50 and older. The FDA is expected to decide by August 5 on licensure, potentially through traditional and accelerated pathways, with Moderna committing to post-marketing trials. The vaccine showed a 27% reduction in confirmed influenza cases compared to standard-dose vaccines, with similar safety profiles but more mild side effects. Experts highlighted mRNA's advantages in manufacturing speed and avoiding egg-related mutations, which could enhance pandemic response efforts, though concerns about higher reactogenicity were noted.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)